CASP1 and metabolic dysfunction-associated steatohepatitis: Next, we clarify whether epalrestat treatment is achieved by inhibiting NLRP3 inflammasome activation in NASH, so active caspase-1 expression and pro-inflammatory cytokine secretion were tested in liver tissue after epalrestat treatment.